LR Health & Beauty SE Sees Growth in Q3 2024

LR Health & Beauty SE reports continued growth in Q3 2024, with sales increasing by 7.2%, reaching EUR 69.4 million. The company's EBITDA rose to EUR 7.3 million, while normalized EBITDA increased to EUR 8.7 million. Key contributors to this growth include the successful launch of LR ZEITGARD Signature and an updated career plan for distributors.

The first nine months of 2024 generated sales of EUR 212.7 million, a 3.4% rise from the previous year. The adjusted guidance forecasts annual sales between EUR 288 million and EUR 292 million, with EBITDA expected to range from EUR 26 million to EUR 29 million.

Despite forecasted one-off impacts in Q4 due to the career plan changes, the company anticipates sustained growth in 2025. The new logistics center in Ahlen is expected to enhance efficiency and scalability, supporting future expansion.